Verified ComparisonLast updated: 19 April 2026
Semaglutide vs Tirzepatide
Both are incretin-based, but tirzepatide adds GIP receptor agonism. Both are approved in Australia.
Semaglutide
Metabolic
4.3/ 5
A−
Tirzepatide
Metabolic
4.6/ 5
A
Editor's note
Tirzepatide has produced higher weight loss in head-to-head data. Semaglutide has the broader CV outcomes evidence base today.
| Criterion | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 | GLP-1 + GIP |
| Weight loss in head-to-head data | Substantial | Higher in published trials |
| Cardiovascular outcomes | Established (SELECT) | Trials ongoing |
| Regulatory status (AU) | Approved | Approved |
Frequently asked questions
Yes.
Want to read the full reviews?